Impact Partnership Wealth LLC Sells 4,529 Shares of Illumina, Inc. $ILMN

Impact Partnership Wealth LLC trimmed its position in Illumina, Inc. (NASDAQ:ILMN) by 57.8% during the fourth quarter, Holdings Channel reports. The firm owned 3,300 shares of the life sciences company’s stock after selling 4,529 shares during the quarter. Impact Partnership Wealth LLC’s holdings in Illumina were worth $433,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently modified their holdings of the company. Elyxium Wealth LLC bought a new stake in shares of Illumina in the 4th quarter valued at about $25,000. Creative Capital Management Investments LLC raised its holdings in shares of Illumina by 160.0% in the 4th quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company’s stock valued at $26,000 after purchasing an additional 120 shares during the period. Board of the Pension Protection Fund bought a new stake in shares of Illumina in the 4th quarter valued at about $26,000. TD Waterhouse Canada Inc. bought a new stake in shares of Illumina in the 4th quarter valued at about $26,000. Finally, Laurel Wealth Advisors LLC bought a new stake in shares of Illumina in the 4th quarter valued at about $26,000. 89.42% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Illumina news, Director Keith A. Meister sold 225,067 shares of the stock in a transaction that occurred on Wednesday, May 13th. The shares were sold at an average price of $145.55, for a total transaction of $32,758,501.85. Following the transaction, the director owned 3,604,441 shares in the company, valued at $524,626,387.55. This represents a 5.88% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Christensen Jakob Wedel sold 700 shares of the stock in a transaction that occurred on Wednesday, May 6th. The stock was sold at an average price of $139.04, for a total transaction of $97,328.00. Following the transaction, the senior vice president owned 15,056 shares in the company, valued at approximately $2,093,386.24. The trade was a 4.44% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 330,160 shares of company stock worth $48,028,308. Company insiders own 2.90% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on ILMN. Royal Bank Of Canada began coverage on shares of Illumina in a report on Thursday, May 14th. They issued an “outperform” rating and a $170.00 target price on the stock. Wall Street Zen cut shares of Illumina from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Daiwa Securities Group raised shares of Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 price target on the stock in a report on Thursday, May 14th. Barclays increased their price target on shares of Illumina from $110.00 to $122.00 and gave the company an “underweight” rating in a report on Friday, May 1st. Finally, JPMorgan Chase & Co. increased their price target on shares of Illumina from $120.00 to $125.00 and gave the company a “neutral” rating in a report on Friday, May 1st. Seven research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $137.75.

Illumina Stock Up 2.7%

Illumina stock opened at $162.96 on Friday. The stock has a market cap of $24.66 billion, a P/E ratio of 29.63, a P/E/G ratio of 2.70 and a beta of 1.42. The company has a quick ratio of 1.36, a current ratio of 1.75 and a debt-to-equity ratio of 0.56. Illumina, Inc. has a twelve month low of $78.79 and a twelve month high of $165.37. The company’s 50-day moving average price is $133.73 and its two-hundred day moving average price is $132.02.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.05 by $0.10. The firm had revenue of $1.09 billion for the quarter, compared to analysts’ expectations of $1.07 billion. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The business’s revenue was up 4.8% on a year-over-year basis. During the same period in the prior year, the firm earned $0.97 EPS. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. As a group, analysts expect that Illumina, Inc. will post 5.2 EPS for the current year.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.